Sorted By:


Part D Costs Less Than Initially Projected

Chartpack  |  From Our Network

Total Part D costs are 45% lower than the initial 10-year cost estimate....

Illustrative Pharmaceutical Lifecycle

Chartpack  |  From Our Network

Over time, brand drugs lose patent protection and generic drugs are introduced, achieving significant cost savings for the Part D program. Savings free up program resources for the next generation of medical advances from innovators....

Biosimilars Labeling

PhRMA  |  Fact Sheet

Food and Drug Administration (FDA)-approved prescription drug labeling is the most authoritative mechanism for communicating information about a medicine’s safety and effectiveness to health care providers.

ICYMI: Ubl weighs in on how fair trade protects US biopharmaceutical innovation

PhRMA  |  Blog Post

America’s biopharmaceutical leadership is a result of a robust medical innovation ecosystem driven by several factors: a free-market economy that rewards innovation, strong intellectual property protections, public sector investments in education and basic sciences, and a reliable rule of law.

PhRMA Announces Major Commitment to Address the Opioid Crisis in America

PhRMA  |  Press Release

To accelerate the development of innovative new treatments and therapies, PhRMA recently announced it’s working to establish a public-private partnership with the National Institutes of Health (NIH), the National Institute on Drug Abuse (NIDA) and leaders in the biopharmaceutical industry.

Statement on Biosimilar User Fee Act Reauthorization

PhRMA  |  Press Release

Key provisions about the BsUFA II performance goals letter: Continue to improve the efficiency of the science-based FDA review process for biosimilars; Establish dedicated staff capacity for key functions, such as facilitating scientific coordination, policy development, operations management, program governance, internal training, educational outreach, and communication; and  Help ensure the long-term sustainability of BsUFA activities through modernized time reporting and capacity planning.

America’s Biopharmaceutical Companies Launch Groundbreaking, Multi-Year Initiative Heralding New Era of Medicine

PhRMA  |  Press Release

Public Health: A public outreach and education campaign around critical public health issues facing America today.

Spurring Innovation in Rare Diseases

PhRMA  |  Fact Sheet

Although rare diseases each may individually only impact a relatively small number of patients, defined as less than 200,000 in the United States, their impact on public health is far-reaching.

This is not a video game: New TV ad showcases the destruction of a cancer cell by immune system

PhRMA  |  Blog Post

Today, as part of our new advertising and public affairs initiative, GOBOLDLY, we are excited to announce the premier of our newest TV advertisement, Cells, which highlights innovative immunotherapy treatments by America’s biopharmaceutical companies.

The Importance of Data-Driven Information Sharing

PhRMA  |  Fact Sheet

In the era of data-driven medicine, fostering informed communications among all stakeholders are critical.

Regulatory Harmonization

PhRMA  |  From PhRMA

Additionally, our member companies agree to PhRMA’s Principles on Conduct of Clinical Trials and Communication of Clinical Trial Results.

Director - Advocacy and Strategic Alliance

PhRMA  |  PhRMA Career

Professional Experience / Requirements Bachelor’s degree in Political Science, Public Policy, Public Health or related field (Master’s degree related discipline preferred; 5+ years of experience working in the patient advocacy community, the Federal government, or with Congress; Sophisticated policy analysis skills; Experience in coalition-building; Strong understanding of FDA regulatory, drug development and approval processes; Understanding of public health programs, including Medicare, Medicaid, and the Affordable Care Act; Understanding of the legislative process; Ability to inspire confidence within the organization and with external constituencies; Must be willing to travel and be both responsive and available after hours and on weekends.

PhRMA response to Washington Post and 60 Minutes stories

PhRMA  |  Blog Post

Recently, we announced our support for a number of more aggressive policies to combat opioid abuse, including a 7-day script limit for acute pain, and our companies are working closely with NIH and FDA on a public-private partnership to bring new non-opioid therapies to market for patients who are in need of appropriate pain medication.

Poll respondents appreciate economic benefits of innovation and call for more protections

PhRMA  |  Blog Post

It’s clear that experts and the general public alike understand the value of innovation and want to ensure that it is properly protected.

PhRMA  |  Biography

The Partnership at works closely with sponsors and supporters, corporate partners, media partners and alliances to develop public education communication campaigns that accomplish their partners’ strategic objectives while enhancing programs to help people live healthy, drug-free lives.

A critical opportunity to prevent prescription drug abuse

PhRMA  |  Blog Post

This is an opportunity to collectively work together to support ongoing educational efforts so the public, patients, caregivers and others understand the dangers of prescription drug abuse and the role they can play in reducing the potential for abuse and misuse.

Senior Manager – Advocacy and Strategic Alliances

PhRMA  |  PhRMA Career

Preferred attributes/skills/experience 3-5 years relevant professional experience; Public affairs, health policy, trade association or Capitol Hill experience.

Opportunities to build upon enhanced competition for medicines in the marketplace

PhRMA  |  Blog Post

Last week, I presented at the U.S Food and Drug Administration’s (FDA) public meeting on the Hatch-Waxman Amendments to discuss the balance between encouraging innovation in biopharmaceutical development and accelerating access to generic alternatives.

PhRMA - MC Poll 4

PhRMA  |  Graphic


PhRMA Principles for Clinical Trial Data Sharing

PhRMA  |  Codes & Guidelines

Biopharmaceutical companies are committed to enhancing public health through responsible sharing of clinical trial data in a manner that is consistent with the following Principles: Safeguarding the privacy of patients Respecting the integrity of national regulatory systems Maintaining incentives for investment in biomedical research

Deputy Vice President – Policy and Research

PhRMA  |  PhRMA Career

Preferred Experience / Requirements J.D. or  master’s degree in Business, Regulatory and/or Scientific Affairs, Health Policy, Public Policy, Public Health or related discipline; Strong negotiating skills/ability to influence and build consensus; Knowledge of legislation, regulation, and analytic research of federal regulatory programs impacting the biopharmaceutical industry; Pharmaceutical company, congressional/advocacy, and/or policy experience; Knowledge of health economics as it relates to the pharmaceutical industry.

PhRMA Statement on Prescription Drug User Fee Act Reauthorization

PhRMA  |  Press Release

Ensures that FDA can hire and retain a strong scientific and medical workforce to advance its public health mission.

Director - IP and Innovation Policy

PhRMA  |  PhRMA Career

Preferred Experience The successful candidate will have: A J.D. or a master’s degree in Business, Health Policy, Public Policy, or related field preferred; Familiarity of intellectual property law, biopharma ecosystem, and R&D process, economics of industry, and pro-innovation policies; Pharmaceutical company, congressional/advocacy, and/or policy experience preferred; Who we are The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier and more productive lives.

Guest Post: Epilepsy Foundation on rare diseases

PhRMA  |  Blog Post

In 2017, we have a unique opportunity to build communities of research around rare epilepsies, and further public policies and federal investments in support of greater innovation with new leadership at the Food and Drug Administration and as Congress looks to reauthorize the Prescription Drug User Fee Act.

Senior Manager – Policy and Research

PhRMA  |  PhRMA Career

Professional Experience / Requirements Master’s degree in Economics, Finance, Statistics, Epidemiology, Health Policy or related field; 1+ years healthcare research and experience managing third party research efforts; Excellent writing and editing skills; Strong interpersonal and communication skills.

You have reviewed the first 175 results out of 883. Each page contains 25 results. You're on page 7.

prev 7 8 9 10 11 12 next